Gene therapy developer Neurogene has appointed Stuart Cobb to serve as its chief scientific officer. Cobb is currently a scientist at the University of Edinburgh. Neurogene says he will split his time between the university and the New York-based company. Neurogene recently raised $68.5 million in Series A financing to support research and development of its pipeline of gene therapies for genetic diseases affecting the brain.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
